SCHEMBL16640316

SCHEMBL16640316

CC(C)c1ccc(-n2c3ccccc3c3cccnc32)nc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.35
PDE4A P27815 4/20 0.34
PDE4B Q07343 3/20 0.34
PDE4C Q08493 3/20 0.34
PDE4D Q08499 3/20 0.34
MAPT P10636 3/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
FEN1 P39748 1/20 0.32
TP53 P04637 1/20 0.32
CCNT1 O60563 1/20 0.32
PIM1 P11309 1/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
CDK9 P50750 1/20 0.32
CDK5 Q00535 1/20 0.32
CDK5R1 Q15078 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16640328 0.87 GRM4 (0.40) GRM4PTGDR2ALDH1A1TSHRSMO
SCHEMBL16640319 0.84 GRM4 (0.35) GRM4MAPTTP53TSHRSMO
SCHEMBL16640318 0.82 PDE4A (0.41) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL16644611 0.82 KMT2A (0.38) MAPTHDAC3HDAC1HDAC2HDAC6
SCHEMBL16640315 0.81 MAOA (0.43) GRM4PTGDR2HDAC3HDAC2HDAC6
SCHEMBL16640320 0.81 MKNK1 (0.35) GRM4MAPTPTGDR2
SCHEMBL15762302 0.78 POLB (0.42) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL15394768 0.77 KDM4E (0.38) PDE4APDE4BPDE4CPDE4DHDAC3
SCHEMBL23490972 0.76 PPARG (0.43) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL25847049 0.75 KDM4E (0.37) PDE4APDE4BPDE4CPDE4DMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11189808-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-11-30 US disclosed
US-20200152891-A1 PLATINUM COMPLEXES AND DEVICES UNIV ARIZONA STATE (US) 2020-05-14 US disclosed
US-10566553-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2020-02-18 US disclosed
US-9947881-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-17 US disclosed
US-9947881-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-17 US disclosed
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2017-01-12 US disclosed
US-9385329-B2 Platinum complexes and devices Arizona Board of Regents on behalf of Arizona State University and Universal Display Corporation (US) 2016-07-05 US disclosed
US-20150105556-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11189808-B2 Platinum complexes and devices OXA1L, OCIAD1, OCIAD2 GRM4 3031/4885PDE4A 4870/4885PDE4B 4878/4885
US-10566553-B2 Platinum complexes and devices OXA1L, OCIAD1, OCIAD2 GRM4 3031/4885PDE4A 4870/4885PDE4B 4878/4885
US-20200152891-A1 PLATINUM COMPLEXES AND DEVICES OXA1L, OCIAD1, OCIAD2 GRM4 3031/4885PDE4A 4870/4885PDE4B 4878/4885
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES OXA1L, OCIAD1, OCIAD2 GRM4 3031/4885PDE4A 4870/4885PDE4B 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.